Date Time
Blood Test for Kidney Rejection Suggests New Treatment
PITTSBURGH– Researchers at the University of Pittsburgh School of Medicine have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give doctors an opportunity to intervene and prevent permanent damage.
These results, published today in Science Translational Medicine, not only identify a warning signal that something is going wrong, but also suggest an existing medication that could be given to these patients to right the course of their long-term recovery.
“We can’t tell a priori if a patient is on too much or too little immune suppression we don’t know until after rejection or an infection has already started,” said senior author David Rothstein, M.D., the Pittsburgh Steelers Chair in Transplantation and professor of surgery, medicine and immunology at Pitt. “We wanted to find something that would tell us this patient is at risk of
E-Mail
IMAGE: Pittsburgh Steelers Chair in Transplantation and professor of surgery, medicine and immunology, University of Pittsburgh School of Medicine view more
Credit: Thomas E. Starzl Transplantation Institute at the University of Pittsburgh
PITTSBURGH, Feb. 24, 2021 - Researchers at the University of Pittsburgh School of Medicine have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give doctors an opportunity to intervene and prevent permanent damage.
These results, published today in
Science Translational Medicine, not only identify a warning signal that something is going wrong, but also suggest an existing medication that could be given to these patients to right the course of their long-term recovery.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to .
electroCoreFebruary 9, 2021 GMT
ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal
Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James’s University Hospital in Leeds, England. The study was funded by the Bowel Research UK supported by the National Institute for Health Research (NIHR) Surgical MedTech Co-operative.